AWS GraphRAG deployment cuts drug research cycles by 87%
AI-summarised brief · reviewed before publication
AWS has deployed a GraphRAG solution that slashes pharmaceutical research‑and‑development cycles by 87 percent. The system merges siloed proprietary databases—including clinical metrics, engineering notes and laboratory records—into a single, queryable knowledge graph built on Amazon Neptune Analytics and powered by Bedrock’s Claude 4.5 Sonnet. Natural‑language queries are parsed, entities are linked to structured nodes, and answers are drawn from both internal data and public sources such as PubMed, with Amazon Comprehend Medical extracting medical codes. The architecture relies on Lambda functions, S3 bulk loading, and SageMaker notebooks, incurring a base cost of $0.48 per hour for a 16‑unit Neptune instance plus token‑usage fees. While the approach accelerates discovery, it demands rigorous schema governance to avoid mis‑mapping and hallucinations.
💡 Why It Matters
- · By turning fragmented research data into an instantly searchable graph, the platform enables scientists to uncover hidden drug‑target relationships in days rather than months, dramatically shortening time‑to‑clinical trials.
